Reciprocal Complementation of the Tumoricidal Effects of Radiation and Natural Killer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yang, Kai Lin ^a   Wang, Yu Shan ^a   Chang, Chao Chun ^a   Huang, Su Chen ^a   Huang, Yi Chun ^a   Chi, Mau Shin ^a   Chi, Kwan Hwa ^a,b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GRANZYME B; PERFORIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; X LINKED INHIBITOR OF APOPTOSIS; CASPASE 9; DIABLO PROTEIN, HUMAN; GRANZYME; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CONTACT; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CASPASE 9; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GRANZYMES; HUMANS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; MITOCHONDRIAL PROTEINS; NEOPLASMS; PERFORIN; RADIATION TOLERANCE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84876695882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061797     Document Type: Article

References (42)

1. Chi KH, Wang YS, Kao SJ, (2012) Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother Radiopharm 27: 6-11.
2. Ahn GO, Brown JM, (2009) Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle 8: 970-976.
3. Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, et al. (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8+ dendritic cells. The Journal of Experimental Medicine 208: 2005-2016.
4. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G, (2006) Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 12: 3355-3360.
5. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, et al. (2012) Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 109: 2491-2496.
6. Shiao SL, Ganesan AP, Rugo HS, Coussens LM, (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes & Development 25: 2559-2572.
7. Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Menard S, et al. (2011) TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res 71: 6382-6390.
8. Cha E, Fong L, (2011) Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches. Journal of Clinical Oncology 29: 3677-3685.
9. Tímár J, Forster-Horváth C, Lukits J, Döme B, Ladányi A, et al. (2003) The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer-A Multicenter Phase I/II Clinical Trial. The Laryngoscope 113: 2206-2217.
10. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, et al. (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11: 3353-3362.
11. Wang YS, Tsang YW, Chi CH, Chang CC, Chu RM, et al. (2008) Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett 266: 275-285.
12. Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, et al. (2005) Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial. J Clin Oncol 23: 3421-3432.
13. Chi CH, Wang YS, Yang CH, Chi KH, (2010) Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activation. Cancer Biother Radiopharm 25: 39-45.
14. Metkar SS, Wang B, Aguilar-Santelises M, Raja SM, Uhlin-Hansen L, et al. (2002) Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 16: 417-428.
15. Campoli M, Ferrone S, (2008) Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72: 321-334.
16. Hersey P, Zhang XD, (2001) How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1: 142-150.
17. Thomas DA, Massague J, (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
18. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr, (1998) NF-kB Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase-8 Activation. Science 281: 1680-1683.
19. Du C, Fang M, Li Y, Li L, Wang X, (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42.
20. Dubrez-Daloz L, Dupoux A, Cartier J, (2008) IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7: 1036-1046.
21. Wu H, Tschopp J, Lin SC, (2007) Smac mimetics and TNFalpha: a dangerous liaison? Cell 131: 655-658.
22. Farooque A, Mathur R, Verma A, Kaul V, Bhatt AN, et al. (2011) Low-dose radiation therapy of cancer: role of immune enhancement. Expert Review of Anticancer Therapy 11: 791-802.
23. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, et al. (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. Journal of Neurochemistry 89: 134-141.
24. Ames E, Hallett WHD, Murphy WJ, (2009) Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clinical & Experimental Immunology 155: 504-513.
25. Liu Q, Hilsenbeck S, Gazitt Y, (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087.
26. Owens TW, Foster FM, Valentijn A, Gilmore AP, Streuli CH, (2010) Role for X-linked Inhibitor of Apoptosis Protein Upstream of Mitochondrial Permeabilization. Journal of Biological Chemistry 285: 1081-1088.
27. Weiner LM, Surana R, Wang S, (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
28. Dietrich P-Y, Dutoit V, Tran Thang NN, Walker PR, (2010) T-cell immunotherapy for malignant glioma: toward a combined approach. Current Opinion in Oncology 22: 604-610.
29. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho H-I, et al. (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. The Journal of Clinical Investigation 120: 1111-1124.
30. Drake CG, (2011) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593.
31. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, et al. (2010) The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 5: 108.
32. Shresta S, Pham CTN, Thomas DA, Graubert TA, Ley TJ, (1998) How do cytotoxic lymphocytes kill their targets? Current Opinion in Immunology 10: 581-587.
33. Wahl SM, Wen J, Moutsopoulos N, (2006) TGF-β: a mobile purveyor of immune privilege. Immunological Reviews 213: 213-227.
34. Wilczynski JR, Radwan M, Kalinka J, (2008) The characterization and role of regulatory T cells in immune reactions. Front Biosci 13: 2266-2274.
35. Deveraux Q, Reed J, (1999) IAP family proteins- suppressors of apoptosis. Genes Dev 13: 239-252.
36. Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, et al. (2010) The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res 70: 1825-1834.
37. Zhou LL, Zhou LY, Luo KQ, Chang DC, (2005) Smac/DIABLO and cytochrome c are released from mitochondria through a similar mechanism during UV-induced apoptosis. Apoptosis 10: 289-299.
38. Westwood JA, Berry LJ, Wang LX, Duong CP, Pegram HJ, et al. (2010) Enhancing adoptive immunotherapy of cancer. Expert Opin Biol Ther 10: 531-545.
39. Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J, (2011) Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiation Oncology 6: 49.
40. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, et al. (2011) Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24: 671-682.
41. Zitvogel L, Casares N, Peuignot MO, Chaput N, Albert ML, et al. (2004) Immune Response Against Dying Tumor Cells. Advances in Immunology: Academic Press. 131-179.
42. Croci D, Zacarías Fluck M, Rico M, Matar P, Rabinovich G, et al. (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunology, Immunotherapy 56: 1687-1700.